Compass Therapeutics (NASDAQ:CMPX) Raised to “Hold” at Wall Street Zen

Compass Therapeutics (NASDAQ:CMPX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other research analysts have also issued research reports about the stock. Lifesci Capital began coverage on shares of Compass Therapeutics in a research note on Monday, October 6th. They issued an “outperform” rating and a $10.00 target price on the stock. D. Boral Capital restated a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Wednesday, November 5th. Compass Point set a $10.00 price objective on shares of Compass Therapeutics in a research note on Monday, October 6th. Guggenheim upped their target price on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.90.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $4.23 on Friday. The business’s fifty day moving average price is $3.78 and its two-hundred day moving average price is $2.99. The firm has a market capitalization of $584.92 million, a price-to-earnings ratio of -9.40 and a beta of 1.48. Compass Therapeutics has a 52 week low of $1.27 and a 52 week high of $4.86.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.06. As a group, research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Trading of Compass Therapeutics

Several hedge funds have recently added to or reduced their stakes in CMPX. Vivo Capital LLC raised its holdings in shares of Compass Therapeutics by 70.0% during the second quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock worth $15,713,000 after acquiring an additional 2,487,443 shares during the period. Vanguard Group Inc. increased its holdings in Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after purchasing an additional 2,212,794 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Compass Therapeutics by 11.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after purchasing an additional 449,868 shares during the period. Nuveen LLC acquired a new stake in shares of Compass Therapeutics in the 1st quarter valued at about $579,000. Finally, Propel Bio Management LLC bought a new stake in shares of Compass Therapeutics in the first quarter valued at about $434,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.